UNITED THERAPEUTICS Corp
Close on Oct 19, 2026
- Market cap
- $24.88B
- P/E (TTM)
- 19.4
- Dividend yield
- –
About United Therapeutics
Pharmaceutical Preparations, SIC 2834
United Therapeutics Corporation is a biotechnology public benefit corporation that develops and commercializes therapies for rare, life-threatening conditions and develops organ manufacturing technologies. Its primary commercial focus is pulmonary arterial hypertension, which it addresses through treprostinil-based therapies including Tyvaso DPI, nebulized Tyvaso, Remodulin, and Orenitram, alongside the phosphodiesterase type 5 inhibitor Adcirca. Nebulized Tyvaso and Tyvaso DPI are also indicated to treat pulmonary hypertension associated with interstitial lung disease. Additionally, the company markets Unituxin, an oncology biologic targeting high-risk neuroblastoma. The company distributes its products primarily to specialty pharmaceutical distributors within the United States and to pharmaceutical distributors internationally.
The company operates globally, selling commercial products across the United States, Canada, Japan, most of Europe, and selected countries in Asia, Latin America, and the Middle East. United Therapeutics maintains principal executive offices in Silver Spring, Maryland, and Durham, North Carolina.
Summary of the business section of United Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- UNITED THERAPEUTICS Corp
- Founded
- 1996
- Headquarters
- Silver Spring, MD
- Address
- 1000 Spring St 20910
- Phone
- (301) 608-9292
- Website
- www.unither.com
- Employees
- 1,400, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Tysons, Virginia
Stock & identifiers
- Ticker
- UTHR
- Exchange
- Nasdaq
- IPO date
- Jun 17, 1999
- Shares outstanding
- 43M, Jul 29, 2026
- Public float
- $11.23B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Sep 23, 2009
- SEC CIK
- 1082554
- CUSIP
- 91307C102
- ISIN
- US91307C1027
- LEI
- 5299005C4HZL4UWROC14
- EIN
- 52-1984749
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martine A. Rothblatt | Chairperson & CEO, Director | 376,038 |
| Paul A. Mahon | EVP & GENERAL COUNSEL | 45,172 |
| James Edgemond | CFO AND TREASURER | 25,506 |
| Michael Benkowitz | PRESIDENT AND COO | 36,462 |
| Nilda Mesa | Director | 5,580 |
| Ray Kurzweil | Director | 13,320 |
| Tommy G. Thompson | Director | 22,480 |
| Judy D. Olian | Director | 5,555 |
| Kevin Tracey | Director | – |
| Jan Malcolm | Director | 450 |
| Linda Maxwell | Director | 2,000 |
| Christopher Patusky | Director | 3,510 |
| Christopher Causey | Director | 4,190 |
| Louis W. Sullivan | Director | 4,440 |
| Victor J. Dzau | Director | – |
| Richard Giltner | Director | 21,884 |
| Raymond Dwek | Director | 4,750 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Martine Rothblatt | $18.04M | $149.88M | $9.42M | $321 | $201 |
| FY2024 Martine Rothblatt | $23.01M | $120.26M | $10.01M | $232 | $156 |
| FY2023 Martine Rothblatt | $16.96M | -$10.81M | $7.00M | $145 | $144 |
| FY2022 Martine Rothblatt | $5.32M | $41.19M | $2.38M | $183 | $139 |
| FY2021 Martine Rothblatt | $3.51M | $50.43M | $1.96M | $142 | $124 |
| FY2020 Martine Rothblatt | $4.81M | $49.92M | $4.15M | $172 | $111 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 1,400 employees working across our 15 locations worldwide.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 13, 2023 | Tender offer | Third-party tender offer for the company's shares |
| Jan 25, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 24, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 2, 2011 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Dec 24, 2008 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |